Annexon to Reveal Key Phase 2 Data at ASRS, Phase 3 Topline Data Expected Q4 2026
ANNX has more than doubled off its 52-week low of $2.03.
Summary
Annexon will present Phase 2 ARCHER baseline characteristics linked to vision loss at ASRS on July 18, 2026. The analysis identifies factors that predict BCVA 15-letter loss, directly informing patient selection for the ongoing Phase 3 ARCHER II trial. This is the first public disclosure of these baseline predictors, which could de-risk the pivotal study. Topline Phase 3 data are expected in Q4 2026, making this a near-term catalyst. The presentation reinforces vonaprument's neuroprotective mechanism and its potential as a first-in-class therapy for geographic atrophy.
At the time of this announcement, ANNX was trading at $5.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $909.3M. The 52-week trading range was $2.03 to $7.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.